RightFit Trial Directory

Breast Cancer clinical trials in New Haven, CT

34 recruiting breast cancer studies with a site in New Haven, CT.

All trials in New Haven, CT · All Breast Cancer trials

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

New Haven, CT · +38 more sites

RecruitingPhase 2NCT06749210

DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY

Sponsor: Ohio State University Comprehensive Cancer Center

New Haven, CT · +1 more sites

RecruitingPhase 1NCT06840886

A Study of PHST001 in Advanced Solid Tumors

Sponsor: Pheast Therapeutics

New Haven, CT · +19 more sites

RecruitingPhase 3NCT06982521

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Sponsor: Relay Therapeutics, Inc.

New Haven, CT · +51 more sites

RecruitingPhase 1NCT06270706

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Sponsor: Pliant Therapeutics, Inc.

New Haven, CT · +15 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

New Haven, CT · +12 more sites

RecruitingPhase 1NCT07578571

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

Sponsor: Immunome, Inc.

New Haven, CT · +3 more sites

RecruitingPhase 1NCT07222267

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

Sponsor: BeOne Medicines

New Haven, CT · +5 more sites

RecruitingNot applicableNCT07214532

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Sponsor: Natera, Inc.

Hartford, CT · New Haven, CT · +47 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

New Haven, CT · +21 more sites

RecruitingPhase 2NCT06923527

Circulating Tumor DNA

Sponsor: Yale University

New Haven, CT · +6 more sites

RecruitingPhase 3NCT06492616

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Sponsor: Stemline Therapeutics, Inc.

New Haven, CT · +175 more sites

RecruitingPhase 1 / Phase 2NCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Sponsor: Gilead Sciences

New Haven, CT · +12 more sites

RecruitingPhase 3NCT05879926

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Sponsor: NRG Oncology

Avon, CT · Bridgeport, CT · Danbury, CT · +1223 more sites

RecruitingPhase 3NCT06072612

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Sponsor: BriaCell Therapeutics Corporation

New Haven, CT · +78 more sites

RecruitingPhase 1NCT06458712

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

Sponsor: Duke Street Bio Ltd

New Haven, CT · +3 more sites

RecruitingPhase not listedNCT06888388

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

Sponsor: Sir Mortimer B. Davis - Jewish General Hospital

New Haven, CT · +4 more sites

RecruitingPhase 1NCT07182149

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Sponsor: Normunity AccelCo, Inc.

New Haven, CT · +17 more sites

RecruitingPhase 3NCT05232916

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

Sponsor: Greenwich LifeSciences, Inc.

New Haven, CT · +50 more sites

RecruitingPhase 3NCT05812807

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Sponsor: Alliance for Clinical Trials in Oncology

Bridgeport, CT · Danbury, CT · Derby, CT · +825 more sites

RecruitingPhase not listedNCT06551116

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Sponsor: Abramson Cancer Center at Penn Medicine

Derby, CT · Fairfield, CT · Glastonbury, CT · +34 more sites

RecruitingPhase 1 / Phase 2NCT05768139

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Sponsor: Eli Lilly and Company

New Haven, CT · +27 more sites

RecruitingPhase 1NCT05768932

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Sponsor: SillaJen, Inc.

New Haven, CT · +10 more sites

RecruitingNot applicableNCT05890677

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

Sponsor: University Hospital, Basel, Switzerland

New Haven, CT · +3 more sites

RecruitingPhase 2NCT06917313

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

Sponsor: Yale University

New Haven, CT · +1 more sites

RecruitingPhase 2NCT06953882

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

Sponsor: Yale University

New Haven, CT

RecruitingPhase 1NCT05989347

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Sponsor: Yale University

New Haven, CT

RecruitingPhase 3NCT04852887

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Sponsor: NRG Oncology

Derby, CT · Fairfield, CT · Glastonbury, CT · +809 more sites

RecruitingPhase 1 / Phase 2NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

Sponsor: 858 Therapeutics, Inc.

New Haven, CT · +13 more sites

RecruitingPhase 4NCT04373564

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

Sponsor: Guerbet

New Haven, CT · +15 more sites

RecruitingPhase 3NCT05929768

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Sponsor: SWOG Cancer Research Network

Avon, CT · Bridgeport, CT · Danbury, CT · +952 more sites

RecruitingPhase 1NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Sponsor: Relay Therapeutics, Inc.

New Haven, CT · +23 more sites

RecruitingPhase 1 / Phase 2NCT04787042

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Sponsor: Simcha IL-18, Inc.

New Haven, CT · +5 more sites

Not yet recruitingPhase 2NCT07458113

Sac-TMT for Active TNBC Brain Metastases

Sponsor: Yale University

New Haven, CT

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.